WO2017007273A9 - 각막질환 또는 결막질환의 치료용 조성물 - Google Patents
각막질환 또는 결막질환의 치료용 조성물 Download PDFInfo
- Publication number
- WO2017007273A9 WO2017007273A9 PCT/KR2016/007416 KR2016007416W WO2017007273A9 WO 2017007273 A9 WO2017007273 A9 WO 2017007273A9 KR 2016007416 W KR2016007416 W KR 2016007416W WO 2017007273 A9 WO2017007273 A9 WO 2017007273A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disease
- extract
- corneal
- maple leaf
- eye
- Prior art date
Links
- 208000021921 corneal disease Diseases 0.000 title claims abstract description 25
- 208000016134 Conjunctival disease Diseases 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 title claims description 18
- 239000000284 extract Substances 0.000 claims abstract description 68
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 23
- 241000510091 Quadrula quadrula Species 0.000 claims description 51
- 201000005111 ocular hyperemia Diseases 0.000 claims description 32
- 201000010099 disease Diseases 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 206010010741 Conjunctivitis Diseases 0.000 claims description 17
- 239000000469 ethanolic extract Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 7
- 239000002537 cosmetic Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 4
- 206010023332 keratitis Diseases 0.000 claims description 4
- 201000002154 Pterygium Diseases 0.000 claims description 3
- 206010006448 Bronchiolitis Diseases 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 claims description 2
- 241000931515 Acer palmatum Species 0.000 claims 1
- 208000028006 Corneal injury Diseases 0.000 abstract description 12
- 230000002401 inhibitory effect Effects 0.000 abstract description 11
- 210000005252 bulbus oculi Anatomy 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 7
- 244000046151 Acer negundo Species 0.000 abstract description 4
- 235000004422 Acer negundo Nutrition 0.000 abstract description 4
- 230000033115 angiogenesis Effects 0.000 abstract description 4
- 206010020565 Hyperaemia Diseases 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- 210000001508 eye Anatomy 0.000 description 32
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 30
- 210000004204 blood vessel Anatomy 0.000 description 20
- 210000004087 cornea Anatomy 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 241000700159 Rattus Species 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 229960002504 capsaicin Drugs 0.000 description 15
- 235000017663 capsaicin Nutrition 0.000 description 15
- 241000208140 Acer Species 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 210000000795 conjunctiva Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 230000006378 damage Effects 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 206010029113 Neovascularisation Diseases 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 208000030533 eye disease Diseases 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 206010055665 Corneal neovascularisation Diseases 0.000 description 4
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 4
- 201000000159 corneal neovascularization Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003889 eye drop Substances 0.000 description 4
- 229940012356 eye drops Drugs 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 3
- 206010013774 Dry eye Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229960003699 evans blue Drugs 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000002695 general anesthesia Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229960002275 pentobarbital sodium Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- LPLLVINFLBSFRP-UHFFFAOYSA-N 2-methylamino-1-phenylpropan-1-one Chemical compound CNC(C)C(=O)C1=CC=CC=C1 LPLLVINFLBSFRP-UHFFFAOYSA-N 0.000 description 2
- 208000034579 Acute haemorrhagic conjunctivitis Diseases 0.000 description 2
- 244000293323 Cosmos caudatus Species 0.000 description 2
- 235000005956 Cosmos caudatus Nutrition 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 201000007032 bacterial conjunctivitis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010015907 eye allergy Diseases 0.000 description 1
- 231100000040 eye damage Toxicity 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 206010023365 keratopathy Diseases 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/20—Aceraceae (Maple family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
- A61Q1/10—Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara
Abstract
Description
점수 | 평가기준 |
0 | 연곽과 외안근 혈관의 정상적 모습 |
1 | 연곽과 외안근 혈관의 일반적 확장 |
2 | 연곽에서 혈관이 분리되어 새로운 혈관의 관찰 |
3 | 열린 안구 결막에서 새로운 혈관의 관찰 |
4 | 열린 안구 결막에서 발적의 확산 |
Claims (9)
- 단풍나무(Acer palmatum) 잎 추출물을 포함하는 각막질환 또는 결막질환의 예방 또는 치료용 약학적 조성물.
- 제1항에 있어서, 상기 단풍나무 잎 추출물은 단풍나무 잎 에탄올 추출물인 것인, 약학적 조성물.
- 제1항에 있어서, 상기 단풍나무 잎 추출물은 단풍나무 잎 열수 추출물인 것인, 약학적 조성물.
- 제1항에 있어서, 상기 각막질환은 안구 충혈, 각막 신생혈관 질환, 및 각막염을 포함하는 군으로부터 선택된 어느 하나인 것인, 약학적 조성물.
- 제1항에 있어서, 상기 결막질환은 결막염, 검열반염, 및 익상편을 포함하는 군으로부터 선택된 어느 하나인 것인, 약학적 조성물.
- 제1항에 있어서, 상기 조성물은 안구 외용제형인 것인, 약학적 조성물.
- 제1항에 있어서, 상기 조성물은 약제학적으로 허용가능한 담체를 추가로 포함하는 것인, 약학적 조성물.
- 단풍나무 잎 추출물을 포함하는 안구충혈의 예방 또는 개선용 화장료 조성물.
- 제1항 내지 제7항 중 어느 한 항의 조성물을 개체의 안구에 투여하는 단계를 포함하는, 각막질환 또는 결막질환의 예방 또는 치료 방법.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311602841.5A CN117379466A (zh) | 2015-07-08 | 2016-07-08 | 用于治疗角膜疾病或结膜疾病的组合物 |
CN201680052055.4A CN108025029B (zh) | 2015-07-08 | 2016-07-08 | 用于治疗角膜疾病或结膜疾病的组合物 |
US15/742,391 US10357528B2 (en) | 2015-07-08 | 2016-07-08 | Composition for treating corneal diseases or conjunctival diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150097387A KR101662720B1 (ko) | 2015-07-08 | 2015-07-08 | 각막질환 또는 결막질환의 치료용 조성물 |
KR10-2015-0097387 | 2015-07-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2017007273A1 WO2017007273A1 (ko) | 2017-01-12 |
WO2017007273A9 true WO2017007273A9 (ko) | 2017-10-26 |
Family
ID=57145268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2016/007416 WO2017007273A1 (ko) | 2015-07-08 | 2016-07-08 | 각막질환 또는 결막질환의 치료용 조성물 |
Country Status (4)
Country | Link |
---|---|
US (1) | US10357528B2 (ko) |
KR (1) | KR101662720B1 (ko) |
CN (2) | CN117379466A (ko) |
WO (1) | WO2017007273A1 (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101762797B1 (ko) * | 2016-04-20 | 2017-07-31 | 한국 한의학 연구원 | 단풍나무 잎 추출물을 포함하는 안구건조증의 예방 또는 치료용 조성물 |
KR20180065933A (ko) * | 2016-12-07 | 2018-06-18 | 한국 한의학 연구원 | 단풍잎 추출물 또는 이의 분획물을 포함하는 염증성 안구질환 예방 또는 치료용 조성물 |
KR102087271B1 (ko) * | 2017-07-10 | 2020-03-11 | 한국한의학연구원 | 신규한 디하이드로-2'H,3H-스피로[퓨란-2,3'-퓨로[3,2-b]퓨란]-2',5(3a'H,4H,5'H)-디온 유도체 및 이를 포함하는 염증성 안구질환 예방 또는 치료용 약학적 조성물 |
KR102138860B1 (ko) * | 2017-07-10 | 2020-07-30 | 한국한의학연구원 | 단풍나무 잎 추출물을 포함하는 안압 저하용 조성물 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9506827A (pt) * | 1994-02-17 | 1997-09-30 | Merck Patent Gmbh | Composição e método antiviróticos ou antifúngicos |
GB0624340D0 (en) * | 2006-12-06 | 2007-01-17 | Nature Therapeutics Ltd | Antimicrobial composition |
KR20100004466A (ko) | 2008-07-04 | 2010-01-13 | 인하대학교 산학협력단 | 신생혈관형성 억제 활성을 갖는 약학적 조성물 |
KR101326162B1 (ko) * | 2009-10-01 | 2013-11-07 | 재단법인 제주테크노파크 | 항염증성 조성물 |
KR101089779B1 (ko) * | 2011-04-29 | 2011-12-07 | 주식회사 청진바이오텍 | 정제봉독, 단풍나무 추출물 및 작살나무 추출물을 유효성분으로 포함하는 기능성 천연 화장료 조성물 |
KR101484948B1 (ko) | 2013-08-08 | 2015-01-22 | 한국과학기술연구원 | 돌단풍 추출물을 포함하는 항알러지용 조성물 |
-
2015
- 2015-07-08 KR KR1020150097387A patent/KR101662720B1/ko active IP Right Grant
-
2016
- 2016-07-08 US US15/742,391 patent/US10357528B2/en active Active
- 2016-07-08 CN CN202311602841.5A patent/CN117379466A/zh active Pending
- 2016-07-08 WO PCT/KR2016/007416 patent/WO2017007273A1/ko active Application Filing
- 2016-07-08 CN CN201680052055.4A patent/CN108025029B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
WO2017007273A1 (ko) | 2017-01-12 |
CN108025029B (zh) | 2023-12-15 |
CN117379466A (zh) | 2024-01-12 |
CN108025029A (zh) | 2018-05-11 |
US10357528B2 (en) | 2019-07-23 |
KR101662720B1 (ko) | 2016-10-07 |
US20180264064A1 (en) | 2018-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017007273A9 (ko) | 각막질환 또는 결막질환의 치료용 조성물 | |
US20120004320A1 (en) | Method for Treating Ocular Demodex | |
TWI558405B (zh) | Cicada active material, a preparation method thereof, a pharmaceutical composition comprising the same and a use thereof | |
WO2021213484A1 (zh) | 秦艽及其单体化合物在杀螨中的应用 | |
JP6874075B2 (ja) | 眼疾患を治療するためのタイワンプロポリス抽出物 | |
CN106659749B (zh) | 包含葎草提取物作为有效成分的用于预防或治疗退行性脑疾病的组合物 | |
WO2018226058A9 (ko) | 콜라겐 타입 ι 및 색소 상피성 인자 펩타이드를 유효성분으로 함유하는 신생혈관질환 예방 또는 치료용 약학조성물 | |
CN109394987B (zh) | 含富马酸二甲酯的具有治疗眼部疾病功效的组合物及其制备方法 | |
Jang et al. | Effect of Ginkgo biloba extract on endotoxin-induced labyrinthitis | |
WO2018230942A1 (ko) | 호장근 추출물 또는 이의 분획물을 포함하는 안구건조증 예방 및 치료용 조성물 | |
CN105853295A (zh) | 一种用于儿童皮肤粘膜炎症护理的外用制剂及其应用 | |
WO2019004775A2 (ko) | 아보카도 오일을 유효성분으로 포함하는 난청의 예방 또는 치료용 약학적 조성물 | |
Tabbara | Trachoma: a review | |
WO2021213485A1 (zh) | 蒲公英及其单体化合物在杀螨中的应用 | |
US20210052493A1 (en) | Non-aqueous anti-parasitic ointment for ophthalmological use | |
CN109568486B (zh) | 一种具有治疗结膜炎功效的组合物及其制备方法 | |
Suresha et al. | Role of demodex infestation in blepharitis and coconut oil as a treatment option | |
US11058736B2 (en) | Method of treating dry eye syndrome using pharmaceutical composition having extract of Terminalia chebula or fraction thereof | |
CA2845625C (en) | Medical composition comprising stauntonia hexaphylla extract | |
WO2022170939A1 (zh) | 无细胞脂肪提取物对视神经损伤的治疗用途 | |
Sahdev et al. | Conjunctivitis: Types, diagnosis and treatment under different therapies | |
Stodola | Demodex update: background, signs and symptoms, and treatment | |
Gupta | Eye Infections: A Review | |
WO2019098615A1 (ko) | 벌개미취 추출물 또는 이의 분획물을 포함하는 안구건조증 예방 또는 치료용 조성물 | |
KR102606948B1 (ko) | 안구 건조증을 치료하거나 예방하는 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16821679 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018500742 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15742391 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16821679 Country of ref document: EP Kind code of ref document: A1 |